The U.S. FDA has granted final approval of CMP Pharma’s new drug application (NDA) for CaroSpir (spironolactone) oral suspension, 25 mg/5mL. The approval marks the first and only FDA-approved oral liquid dosage form of the potassium-sparing diuretic spironolactone.   “CaroSpir provides a stable, ready to use and consistent liquid treatment option for adult patients, including those who have difficulty swallowing, or who cannot swallow tablets,” said Gerald Sakowski, chief executive officer, CM...